INIS
cancer
100%
therapy
100%
prostate
100%
metastases
100%
androgens
66%
clinical trials
33%
hormones
33%
patients
33%
men
33%
prednisone
33%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Androgen
100%
Overall Survival
50%
Hormone
50%
Docetaxel
50%
Prednisone
50%
Abiraterone
50%
Clinical Trial
50%
Nursing and Health Professions
Prostate Cancer
100%
Combination Therapy
100%
Androgen
66%
Health Care Quality
33%
Overall Survival
33%
Hormone
33%
Prednisone
33%
Docetaxel
33%
Abiraterone
33%
Medicine and Dentistry
Combination Therapy
100%
Prostate Cancer
100%
Expectation
33%
Overall Survival
33%
Prednisone
33%
Hormone
33%
Docetaxel
33%
Abiraterone
33%
Patient
33%
Man
33%
Neuroscience
Androgen
100%
Prednisone
50%
Docetaxel
50%
Prostate
50%
Expectations
50%
Abiraterone
50%
Veterinary Science and Veterinary Medicine
Prostate Cancer
100%
Prednisone
50%
Abiraterone
50%